Glucagon‐like peptide‐1 receptor agonist

Results 141 to 150 of about 34,140,631 (244)

Gut microbiota dysbiosis in the inflammatory pathogenesis of diabetic retinopathy

VIEW, EarlyView.
This graphical abstract illustrates how gut dysbiosis drives diabetic retinopathy through the gut‐retina axis, a process unfolding in three interconnected stages. First, in the gut, a decrease in beneficial bacteria and an increase in pro‐inflammatory taxa compromise the intestinal barrier, causing a “leaky gut” that allows LPS to translocate into the ...
Junyan Hu, Jingxiang Zhong
wiley +1 more source

Specialty-based variation in glucagon-like Peptide-1 receptor agonist prescribing practices for adolescent obesity in Saudi Arabia. [PDF]

Obes Pillars
Kalagi F, Bah S, Algindan Y.
europepmc +1 more source

Dipeptidyl Peptidase‐4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination

The Journal of Dermatology, EarlyView.
ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Jaein Lee, Jae Hyun Bae, Seokyung Hahn
wiley +1 more source

Anterior Cutaneous Nerve Entrapment Syndrome From Glucagon-Like Peptide-1 Receptor Agonist Injection. [PDF]

ACG Case Rep J
Singh N, Chaparro E, Shapiro JM, Husu EN. +3 more
europepmc +1 more source

Glucagon‐like peptide‐1 receptor agonist use and violent crime among US adults

Criminology, EarlyView.
Abstract Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), a class of medications widely prescribed for diabetes and obesity, have exhibited emerging effects on substance use, reward processing, and impulse control. This study examines whether current GLP‐1 RA use moderates established behavioral pathways to violent crime from impulsivity and ...
Daniel C. Semenza, Christopher Thomas
wiley +1 more source

Body composition in glucagon-like peptide-1 receptor agonist therapy: Absolute loss, relative changes, and outcomes. [PDF]

Hepatol Forum
Chen S +5 more
europepmc +1 more source

Peri‐operative glucagon‐like peptide‐1 receptor agonist use and outcomes: a national prospective multicentre cohort study

Anaesthesia, EarlyView.
Summary Introduction Peri‐operative glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) use is associated with delayed gastric emptying. It is unclear what proportion of patients having anaesthetic care are receiving GLP‐1 RAs; what strategies are used in their peri‐operative management; and whether the incidence of pulmonary aspiration and/or ...
Thomas E. Potter +862 more
wiley +1 more source

Immediate allergy against glucagon-like peptide-1 receptor agonist liraglutide. [PDF]

Asia Pac Allergy
Özdemir Ö.
europepmc +1 more source

Peri‐operative management of patients having day surgery: a consensus statement from the Association of Anaesthetists, British Association for Day Surgery and the Association of Paediatric Anaesthetists, Great Britain and Ireland

Anaesthesia, EarlyView.
Summary Introduction Day surgery is now recognised widely as being a vital component of modern healthcare delivery with overall day surgery rates in the UK now > 85%. Day surgery offers an enhanced experience for patients with reduced risk of postoperative complications (e.g.
Craig R. Bailey +8 more
wiley +1 more source

Effects of Glucagon-Like Peptide-1 Receptor Agonist Use After Transient Ischemic Attack on Risks of Subsequent Ischemic Stroke and Mortality. [PDF]

J Clin Neurol
Kakadiya J +19 more
europepmc +1 more source

medicine
glucagon-like peptide-1 receptor agonist
obesity

science
tirzepatide
clinical endocrinology

diseases of the endocrine glands